scholarly article | Q13442814 |
review article | Q7318358 |
P2093 | author name string | K Shannon | |
C M Tanner | |||
G F Wooten | |||
P Huang | |||
B Ravina | |||
K Kieburtz | |||
B C Tilley | |||
NET-PD Investigators | |||
Y Y Palesch | |||
J J Elm | |||
G C Goetz | |||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Parkinson's disease | Q11085 |
P304 | page(s) | 628-633 | |
P577 | publication date | 2006-03-01 | |
P1433 | published in | Neurology | Q1161692 |
P1476 | title | Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs | |
P478 | volume | 66 |
Q30407150 | A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results |
Q36576472 | Advances in designs for Alzheimer's disease clinical trials. |
Q46823146 | Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? |
Q55112408 | Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. |
Q51158231 | Clinician-trialist rounds: 18. Should young (and old!) clinician-trialists perform single-arm Phase II futility trials? |
Q42616360 | Combination therapies for traumatic brain injury: prospective considerations |
Q37675595 | Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial |
Q24193947 | Creatine for Parkinson's disease |
Q53220635 | Design of phase II ALS clinical trials. |
Q37622166 | Developmental susceptibility of neurons to transient tetrahydrobiopterin insufficiency and antenatal hypoxia-ischemia in fetal rabbits |
Q30407589 | Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial |
Q33964112 | Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial |
Q40494176 | Emtonjeni-A Structural Intervention to Integrate Sexual and Reproductive Health into Public Sector HIV Care in Cape Town, South Africa: Results of a Phase II Study |
Q28284355 | Huntington's disease |
Q30431912 | Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease |
Q34658560 | Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial |
Q26995786 | Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments |
Q29616300 | Neuroinflammation in Parkinson's disease: a target for neuroprotection? |
Q37203405 | Neuroprotection in Parkinson's disease: myth or reality? |
Q50073420 | New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States. |
Q37172826 | Optimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: the FS-TOO resource utilization substudy |
Q38056875 | Overcoming obstacles in Parkinson's disease |
Q80970949 | Parkinson's disease |
Q30357397 | Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. |
Q34508143 | Seniors with Parkinson's disease: initial medical treatment |
Q90597542 | Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study |
Q91268058 | Statistical advances in clinical trials and clinical research |
Q37161380 | Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans |
Q45305395 | TRACK-HD: both promise and disappointment |
Q37302453 | Targets for neuroprotection in Parkinson's disease |
Q36264697 | The futility study--Progress over the last decade |
Q38380170 | The promise of futility trials in neurological diseases. |
Search more.